Clear Harbor Asset Management LLC Makes New $799,000 Investment in Boston Scientific Corporation $BSX

Clear Harbor Asset Management LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 18,726 shares of the medical equipment provider’s stock, valued at approximately $799,000.

Several other institutional investors also recently modified their holdings of BSX. First Nebraska Trust Co bought a new stake in Boston Scientific in the 2nd quarter worth about $4,915,000. Bank of Nova Scotia bought a new position in Boston Scientific during the 2nd quarter valued at about $56,496,000. Kirtland Hills Capital Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $416,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $1,314,000. Finally, Alta Advisers Ltd bought a new stake in shares of Boston Scientific in the second quarter worth approximately $247,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Oppenheimer cut their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Citigroup lowered their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen dropped their price target on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $50.39 on Monday. The business has a 50-day simple moving average of $46.34 and a two-hundred day simple moving average of $57.62. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The stock has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company posted $0.75 EPS. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.